Janssen's Hatch-Waxman dispute with Teva over paliperidone palmitate treatment claims produced a detailed Federal Circuit decision on obviousness and written description.
Teva stipulated to infringement but challenged the asserted patent on validity grounds. The appellate dispute followed remand proceedings and focused on whether the district court correctly handled the clinical and dosing evidence.
For drug-patent strategy, the case belongs in the 2025 life-sciences archive because method-of-treatment claims often rise or fall on whether claimed dosing regimens are sufficiently supported and nonobvious over clinical references.
The broader commercial issue is generic timing: even when infringement is stipulated, validity can decide the practical launch path.